Trial Profile
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Safety and Efficacy Study of Recombinant Human TNF Receptor-IgG Fusion Protein for Injection (Qiangke) to Treat Moderate to Severe Plaque Psoriasis
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- 14 Mar 2016 New trial record